Total number of shares and voting rights in Zealand as of 31 December 2016

Print
| Source: Zealand Pharma A/S
multilang-release

51-16_1231 Share capital end December 2016.pdf

Company announcement - No. 51 / 2016

 

Total number of shares and voting rights in Zealand as of 31 December 2016

Copenhagen, 31 December 2016 - In accordance with Section 10 of the Danish Statutory Order on Issuers' Disclosure Obligations, Zealand issues announcements to state the total number of shares and voting rights in the company at the end of a calendar month in which there have been changes to its share capital. 

In company announcement no. 49 / 2016 on 8 December 2016, Zealand announced increase in its share capital after exercise of employee warrants. Following this announcement, the table below lists the total number of shares and voting rights in Zealand as of 31 December 2016:

 

Date
Number of shares
(nominal value of DKK 1 each)
Share capital
(nominal value in DKK)
Number of voting rights
31 December 2016 26,142,365 26,142,365 26,142,365

                                                                                                                                        
*****

For further information, please contact:

Mats Blom, Senior Vice President, Chief Financial Officer
Tel: +45 31 53 79 73, email: mabl@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under licence collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of proprietary product candidates which primarily target specialty diseases with significant unmet needs.

The company's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Lyxumia® outside the United States and approved as Adlyxin(TM) in the United States. Lixisenatide has been developed in a fixed-ratio combination with basal insulin glargine (Lantus®) and is approved as Soliqua(TM) 100/33 in the United States, and in Europe a CHMP positive opinion recommendation was given in November (Suliqua(TM) is the brand name in Europe). 

Zealand's proprietary pipeline includes: Dasiglucagon* (ZP4207) (single-dose rescue treatment) for acute, severe hypoglycaemia (Phase II); Glepaglutide* (ZP1848) for short bowel syndrome (Phase II); Dasiglucagon* (ZP4207) (multiple-dose version) intended for use in a dual-hormone artificial pancreas system for better hypoglycaemia control and diabetes management (Phase II); and other earlier stage clinical and preclinical peptide therapeutics.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.
* Dasiglucagon and Glepaglutide are proposed International Nonproprietary Names (pINN).

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/bdb2b2b8-4cd8-4384-82b6-6a5c133109df